CareDx Supports Momentum in Medicare Immunosuppressive Medication Legislation

NEXT STORY
Dova Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for DOPTELET® (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP)
PREV STORY
Apellis Pharmaceuticals Completes Enrollment of Phase 3 APL-2 (pegcetacoplan) Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis

author_avatar
NASDAQ Market News

Boehringer Ingelheim and OSE Immunotherapeutics to Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021

author_avatar
NASDAQ Market News

Clover Health, Mass. General, and ACP Decisions Research Team Secures Grant from National Institute of Health for Innovative Approach to Advance Care Planning

author_avatar
NASDAQ Market News